Background: Human papillomavirus (HPV) causes the most prevalent sexually transmitted infection and is an important etiological factor in genital cancer. HPV infection manifests in broad spectrum, from genital warts to cervical intraepithelial neoplasia and cancers. Genital warts remain a frequent problem in primary care. Current modalities provide unsatisfactory result in curing genital warts completely. To date, there are many convincing studies encouraging oral inosine pranobex as an adjuvant therapy to improve postconventional therapy cure-rate. Aim: To assess the efficacy of inosine pranobex as an adjuvant oral therapy in anogenital warts. Methods: Literature search was performed using Pubmed, Ebsco and Science Direct database. Inclusion criteria were human subjects, randomized controlled trial on patients with genital warts, and inosine pranobex as adjuvant therapy. The studies were appraised and findings were formulated to find the best evidence for collating recommendations in treating genital warts patients. Results: There were three articles related to the clinical questions. All articles were found to be valid after selection based on exclusion and inclusion criteria. Discussion: All articles recommended the addition of oral inosine pranobex as an adjuvant therapy in treating patient with genital warts. Based on the critical appraisal performed previously, addition of oral inosine pranobex may minimize conventional therapy failure. Conclusion: Based on the best evidence available, we would recommend the addition of oral inosine pranobex as adjuvant for treating genital warts, except in special conditions, such as for patients with financial problem as this therapy was not covered by national health insurance.
Background
Human papillomavirus (HPV) are a group of DNA viruses that infect human epithelial cells. It causes the most prevalent sexually-transmitted infection and is an important etiological factor in the development of genital cancer. Up to 79 percent of sexually-active women have a genital HPV infection during their lifetime. The peak prevalence occurs in their early 20s. 1 HPV infection may manifest in broad spectrum, from genital warts to cervical intraepithelial neoplasia and cervical and other type of cancers. It depends on the types of HPV and the viral loads. 2 Genital warts caused by HPV infection remains a frequent problem in primary care. There are many modalities to cure genital warts, such as chemical treatments and ablative treatments. None of them gives satisfactory result in totally curing genital warts. To date, there are many convincing studies, which encourage oral inosine pranobex as an adjuvant treatment to improve postconventional therapy cure-rate. 2, 3 Inosine pranobex could induce differentiation of T-cell and enhance lymphoproliferative responses against virus. 4
Case Illustration
A 23-year-old female was referred to our division due to vulvar warts. Physical examination showed multiple vulvar warts and cervical condyloma acuminata. Her vulvar warts and cervical condyloma acuminata had been removed by the doctor. In the doctor's clinical experience, genital warts tend to recur frequently.
The initial treatment plan was a combination of oral immunomodulatory drug, such as inosine pranobex, and conventional therapy to achieve total remission and lower the recurrence rate of the vulvar warts and cervical condyloma acuminata. Medical literature search was performed for the evidence on the efficacy of available immunomodulator (inosine pranobex) to improve the cure rate of condyloma acuminata. 
Clinical question

Methods
Literature search procedures were performed using several leading Twenty-three titles were obtained; the selection of literature was conducted based on title/abstract and elimination of duplicates. Further selection was conducted based on inclusion and exclusion criteria as shown in the flowchart (Appendix 1). Three articles appropriate for the issue were obtained.
Critical Appraisal
The articles were independently appraised, using standardized criteria. Disagreement between researchers was resolved through a discussion.
Results
Using our searching strategy, three RCT articles were included (Georgala et al.; 5 Davidson-Parker J, et al.; 6 and Mohanty KC, et al. 7 ). Descriptions of PICO from each article are listed in Table 2 . Validity, importance, and relevance comparison are explained in Table 2 .
Discussion
HPV causes the most prevalent sexuallytransmitted infection worldwide and is responsible as an etiological factor of cancer development. 1 In our center (Cipto Mangunkusumo Hospital), the prevalence has been increasing in the last three years (20.29%, 24.05%, and 35.16% in 2012, 2013, and 2014, respectively). 8 There are numerous treatment modalities for genital warts, such as chemical treatments and ablative treatments. 1 Yet despite this fact, all modalities are met with a high recurrence rate. 9 To date, although conventional therapies for genital warts can remove most warts, no single treatment modality is more superior to the others, both in terms of completely curing the warts and preventing its recurrence. 3 Recently, inosine pranobex has been introduced as an orally-consumed non-specific immunostimulant. Inosine pranobex is a synthetic purine derivative with immunomodulatory and antiviral properties. 2 Inosine pranobex was studied in several diseases including genital warts and other viral infection. 8 A study conducted by Petrova, et al. (2010) 3 demonstrated a significant pharmacological activity in subclinical HPV infection of the vulva and should be considered as an alternative treatment for the condition. 9 Unfortunately, there are not many prospective studies on inosine pranobex treatment in HPV infection which manifests as genital warts. Based on the previous evidence, inosine pranobex may give promising result in improving the cure rate and lowering the recurrence rate of HPV-related genital wart. We found three randomized controlled trials which were conducted to assess whether inosine pranobex improved the efficacy the conventional treatments in patients with genital wart.
Previous study from Davidson-Parker, et al. (1988) 6 showed that there was a significant effect in eradicating the warts by the end of the study period (p<0.05). This study also showed that there was a significant reduction in the extent of the anogenital and genital warts at the end of the study compared with the classifications on entry which was seen only in patients receiving inosine pranobex (p=0.05). The weakness of this study was a high percentage of loss-to-follow up patients (>20%). 6 7 demonstrated that supplementation of inosine pranobex to the conventional therapy increased the success rate from 41% to 94%. Inosine pranobex was well-tolerated, and none of the patients reported side effects. Furthermore, immunological studies showed an increased number of B cells in 21% of peripheral blood samples. 7 This study was considered valid based on the fulfillment of validity criteria
All articles showed us a decent importance. Based on the critical appraisal done previously, addition of oral inosine pranobex may minimize conventional therapy failure (Absolute risk reduction 0.54 (0.42-0.66), 0,28 (0,21-0,35) and 0.23 (0.03 -0.43) for the first, second, and third article, respectively). Based on the ARRs, the NNTs were 2 (1.5-2.4), 4 (2.9-4.8) and 5 (2.3-33) for the first, second, and third article, respectively. This means that 2 -5 persons need to be treated to get one additional good effect.
Based on their importance, these articles were assessed for their applicability in our clinical practice. Looking at the genital warts' prevalence in our center, the risk of the outcome (treatment failure if inosine pranobex is not given as adjuvant therapy) in our patient, relative to the patients in these trial ranges from 5.3 to 12.2. Our patients did not considerably differ from the patients in the trials, and this fact encourages the addition of inosine pranobex as an adjuvant therapy for improving the cure rate of genital warts.
Due to this validity, importance and applicability assessment, we would like to recommend the addition of inosine pranobex as an adjuvant therapy for genital warts. In Indonesia, there are seven available brands of inosine pranobex, namely: Isoprinosine©, Isprinol©, Laprosin©, Methisoprinol©, Pronovir©, Viridis©, Visoprine©. Unfortunately, the unit costs were IDR 8.000/tablet, IDR 6.380/tablet and IDR 3.000/ tablet, for Isoprinosine©, Viridis©, and Methisoprinol©, respectively; 10 and for the standard dosage of 50 mg/kg body weight, an average adult of 60 kgs would require six tablets daily. To date, inosine pranobex hasn't been covered by public health insurance in Indonesia. Hence, the decision of prescribing inosine pranobex as an adjuvant therapy for genital warts should be made by considering its suitability, cost, efficacy, and affordability, as well as the patient's preference.
Conclusion
Based on the best evidence available, we would recommend the addition of oral inosine pranobex as adjuvant to conventional therapy for genital warts, regardless of financial issue. Therefore, we need to conduct another study with a better clinical trial method (double blind, randomized) in the future.
